# Development of Site-specific Arg-GlcNAc Antibodies

> **NIH NIH R43** · GLYCOSCIENTIFIC, LLC · 2020 · $148,483

## Abstract

Human pathogenic gram-negative bacteria, such as Escherichia coli (E. Coli) and
Salmonella enterica cause millions of deaths, thousands of fatalities and billions of dollars in
medical expenses and lost wages. A critical process that enables these organisms to overcome
the hosts immune response is the injection of proteins directly into infected mammalian (host)
cells. Some of these injected effectors, function as enzymes that modify the structure/function of
the host proteins, which in turn diminish the cells' ability to fight off the infection. One family of
these enzymes are N-glycosyltransferases, which appear to play critical, but yet unknown,
function in pathogenicity. These enzymes add a single α-N-acetyl-D-glucosamine (GlcNAc) to
the guanidinium groups of arginine residues. The primary focus of this application is to
evaluate/develop methodology that will enable the generation of site-specific α-N-GlcNAc
antibodies. We feel that this ability will open the door to the creation of a wide range of Abs that
will have a wide-ranging impact the fields of pharmacy, microbiology, and biochemistry.

## Key facts

- **NIH application ID:** 9925239
- **Project number:** 5R43GM133288-02
- **Recipient organization:** GLYCOSCIENTIFIC, LLC
- **Principal Investigator:** Marla Popov
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $148,483
- **Award type:** 5
- **Project period:** 2019-05-02 → 2022-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9925239

## Citation

> US National Institutes of Health, RePORTER application 9925239, Development of Site-specific Arg-GlcNAc Antibodies (5R43GM133288-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9925239. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*